Moscow disappointed over new US sanctions against Russian companies - Foreign MinistryRussian Politics & Diplomacy March 26, 1:28
US sanctions 8 Russian companies over non-proliferation lawWorld March 25, 21:53
Russia's Defense Ministry says US-led coalition unlikely to launch battle for Raqqa soonRussian Politics & Diplomacy March 25, 19:06
Russia cuts oil production by 185,000 barrels per day as of today — energy ministerBusiness & Economy March 25, 18:30
OPEC has no objections to speed of Russia's oil production cutsBusiness & Economy March 25, 12:38
Opposition leader Vladimir Neklyayev detained in Belarus - news agency directorWorld March 25, 5:33
Russia submits amicus curiae brief to US Supreme CourtRussian Politics & Diplomacy March 25, 3:34
Russia, China suggest for UN SC to adopt resolution on chemical terrorism threatRussian Politics & Diplomacy March 25, 3:23
Russian lawmaker compares European Union to Soviet UnionRussian Politics & Diplomacy March 25, 3:16
TOKYO, Sept. 1, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (Tokyo Stock Exchange: 4568; hereafter Daiichi Sankyo) announced on September 1 details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe.
The TaNeDS program was launched in Japan in 2011 to help discover new lines of research through open innovation. From 2013, it expanded abroad, opening up to researchers in Germany, Switzerland and Austria, and becoming known as the TaNeDS Global Program. Now, in 2014, it has expanded further across Europe to include all EU member countries. The program is conducted with the aim of realizing Daiichi Sankyo's corporate slogan of "Passion for Innovation. Compassion for Patients.(TM)" through increasing collaborative opportunities with researchers in Europe. U3 Pharma GmbH (headquarters: Munich, Germany; hereafter, U3 Pharma), a wholly owned subsidiary of Daiichi Sankyo, is also participating in the program in order to nurture the seeds of drug discovery for the next generation.
(1) Countries where research could be conducted:
All EU member countries plus Norway and Switzerland.
(2) Overview of research programs
Daiichi Sankyo seeks innovative technological research collaborators for novel drug discovery and testing projects that could result in novel drug discovery and novel new drugs.
(3) Research themes
New targeted and investigative research for small-molecule and biologic treatments (antibody drugs, etc.).
2. Cardiovascular and metabolic disorders
New mechanisms and drug treatments for obesity, kidney and renovascular- related disorders.
3. Other disorders
New mechanisms and drug treatments for genetic disorders, new drug treatments for pain, genetic analysis and new drug research for rare diseases.
4. Revolutionary drug discovery technology
New biologic technology, target molecules and delivery systems for nucleic acid treatments, new technology for drug development based on protein structural analysis.
For more details, please visit the TaNeDS Global Programme page at: www.daiichisankyo.com
(4) Budget and period of research
Up to 150,000 euros per year for collaborative research projects lasting up to 2 years.
Researchers of any nationality employed by universities, research institutes and start-up companies within the EU, as well as Norway and Switzerland, who can conduct research in those countries on projects that match Daiichi Sankyo's desired research themes.
(6) Selection process
Daiichi Sankyo and U3 Pharma researchers will select research projects that match their research needs as well as demonstrate originality, potential and promise as drug discovery candidates.
Application period: October 1 to November 15, 2014
First shortlist selection period: Mid-November to mid-December 2014
Second shortlist selection period: Mid-December 2014 to early February 2015
Start of research programs: From mid-April 2015
Selection Results for the TaNeDS Global Program 2013
The application process for 2013 resulted in 2 projects being selected and those collaborations are currently underway.
(1) Applications 49
(2) Selected 2
The two selected laboratories, from the University of Wuertzburg in Germany and the Medical University of Innsbruck in Austria, are both conducting research in the field of cancer therapy.
Representative: Joji Nakayama, Representative Director, President and CEO
(Code No.: 4568, First Section, Tokyo Stock Exchange)
Toshiya Kondo, Senior Director, Public Relations Group Corporate Communications Department Daiichi Sankyo Company, Limited